Wingstop Flies on Q2 Figures
Wingstop Inc. (NASDAQ: WING) shares gained sharply Wednesday, as the Dallas-based restaurant chain announced financial results for the fiscal second quarter ended June 28, 2025. Total revenue for the quarter 2025 increased to $174.3 million from $155.7 million in the prior fiscal second quarter. Royalty revenue, franchise fees and other increased $8.7 million, of which $9.8 million was due to net new franchise development, partially offset by a decrease of $1.4 million due to a 1.9% decline in domestic same store sales. Advertising fees increased $7.3 million due to a 13.9% increase in system-wide sales in the fiscal second quarter 2025, as well as an increase in the national advertising fund contribution rate to 5.5% from 5.3%, effective the first day of the fiscal first quarter 2025. Company-owned restaurant sales increased $2.6 million due to company-owned restaurant same store sales growth of 3.6%, driven primarily by an increase in transactions, as well as company-owned restaurants opened and acquired since the prior fiscal second quarter.Cost of sales was $24.4 million compared to $22.7 million in the prior fiscal second quarter. As a percentage of company-owned restaurant sales, cost of sales decreased to 75.2% from 75.9% in the prior fiscal second quarter. The decrease was primarily driven by sales leverage on labor and other operating expenses.WING shares spread its wings and gained $75.75, or 26.1%, to begin Wednesday at $366.05.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


